For the year ending 2025-12-28, ILMN had $291M increase in cash & cash equivalents over the period. $931M in free cash flow.
| Cash Flow | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 |
|---|---|---|---|---|
| Revenue-Core Illumina | 4,343 | 4,332 | - | - |
| Cost of revenue-Core Illumina | 1,473 | 1,424 | - | - |
| Research and development-Core Illumina | 967 | 988 | - | - |
| Selling and marketing-Core Illumina | 618 | 638 | - | - |
| General and administrative-Core Illumina | 468 | 262 | - | - |
| Goodwill and intangible impairment-Core Illumina | 0 | 3 | - | - |
| Legal contingency and settlement-Core Illumina | -10 | 456 | - | - |
| Revenue-GRAILInc. | 0 | 55 | - | - |
| Total operating expenses-GRAILInc. | 0 | 2,360 | - | - |
| Consolidated other income (expense), net-GRAILInc. | -279 | -346 | - | - |
| Consolidated provision for income taxes-GRAILInc. | 236 | 44 | - | - |
| Net (loss) income | - | - | - | -4,404 |
| Net income (loss) | 850 | -1,223 | -1,161 | - |
| Depreciation expense | 203 | 224 | 235 | 215 |
| Amortization of intangible assets | 67 | 130 | 197 | 179 |
| Share-based compensation expense | 275 | 370 | 380 | 366 |
| Accretion of debt discount on convertible senior notes | - | - | 0 | 0 |
| Deferred income taxes | -119 | 112 | 33 | 23 |
| Goodwill and intangible (ipr&d) impairment | - | - | 827 | 3,914 |
| Gain on previously held investment in grail | - | - | 0 | 0 |
| Payment of accreted debt discount | - | - | 15 | - |
| Gain on exchange of grail contingent value rights | - | - | 0 | 0 |
| Gain on derivative assets related to terminated acquisition | - | - | 0 | 0 |
| Net (gains) losses on strategic investments | 328 | -312 | -40 | -122 |
| Change in fair value of contingent consideration liabilities | -18 | -315 | -24 | -205 |
| Goodwill and intangible (ipr&d) impairment | - | 1,889 | - | - |
| Goodwill and intangible impairment | 23 | - | - | - |
| Property and equipment and right-of-use asset impairment | 4 | 46 | 100 | - |
| Non-cash charitable contribution | 19 | - | - | - |
| Unrealized loss on foreign exchange translation | - | - | -22 | - |
| Gain on helix contingent value right | 0 | 15 | 10 | -7 |
| Other | -18 | -14 | -10 | -17 |
| Accounts receivable | 108 | 25 | 40 | 12 |
| Inventory | 17 | -19 | 20 | 135 |
| Prepaid expenses and other current assets | 8 | 14 | -11 | -16 |
| Operating lease right-of-use assets and liabilities, net | 34 | 32 | 16 | 8 |
| Other assets | 21 | 15 | -5 | -19 |
| Accounts payable | 2 | -4 | -44 | -38 |
| Accrued liabilities | 0 | -440 | 15 | 381 |
| Other long-term liabilities | 33 | 28 | -1 | -19 |
| Net cash provided by operating activities | 1,079 | 837 | 478 | 392 |
| Maturities of available-for-sale securities | - | - | 0 | 0 |
| Purchases of available-for-sale securities | - | - | 0 | 0 |
| Sales of available-for-sale securities | - | - | 0 | 0 |
| Net purchases of property and equipment | 148 | 128 | 195 | 286 |
| Net sales (purchases) of strategic investments | -103 | 52 | 6 | 40 |
| Cash received for derivative assets related to terminated acquisition | - | - | 0 | 0 |
| Cash paid for acquisitions and intangible assets, net of cash acquired | 10 | 81 | 29 | 85 |
| Cash paid for intangible asset | - | - | 1 | 180 |
| Cash received for helix contingent value right | 0 | 83 | - | - |
| Net cash used in investing activities | -55 | -178 | -231 | -591 |
| Common stock repurchases | 742 | 116 | - | 0 |
| Taxes paid related to net share settlement of equity awards | 40 | 32 | 40 | 54 |
| Proceeds from issuance of common stock | 44 | 56 | 67 | 63 |
| Payments on contingent consideration liabilities | 1 | 1 | 1 | 0 |
| Debt issuance costs paid for credit facility | - | - | 1 | - |
| Proceeds from debt, net of issuance costs | 495 | 1,241 | 0 | 991 |
| Payments on debt obligations | 500 | 750 | 1,235 | - |
| Grail cash deconsolidated as a result of spin-off | 0 | 968 | - | - |
| Net cash used in financing activities | -744 | -570 | -1,210 | 1,000 |
| Effect of exchange rate changes on cash and cash equivalents | 11 | -10 | 0 | -22 |
| Net increase (decrease) in cash and cash equivalents | 291 | 79 | -963 | 779 |
| Cash and cash equivalents at beginning of period | 1,127 | 1,048 | 2,011 | 1,232 |
| Cash and cash equivalents at end of period | 1,418 | 1,127 | 1,048 | 2,011 |
ILLUMINA, INC. (ILMN)
ILLUMINA, INC. (ILMN)